Yüklüyor......

Regulation of cell survival by HUNK mediates breast cancer resistance to HER2 inhibitors

Breast cancer patients who are HER2-positive receive targeted inhibitors to HER2, including trastuzumab and lapatinib. While patients benefit from the use of HER2 inhibitors, many fail therapy and almost all patients become resistant to treatment, indicating a critical need to prevent treatment fail...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Breast Cancer Res Treat
Asıl Yazarlar: Yeh, Elizabeth S., Abt, Melissa A., Hill, Elizabeth G.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer US 2014
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4342830/
https://ncbi.nlm.nih.gov/pubmed/25515931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-014-3227-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!